Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing
New company unveiled at the annual ISCT conference in New Orleans combines two tenured and innovative CDMOs with a testing powerhouse
PHILADELPHIA, May 7, 2025 /PRNewswire/ -- Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies ™, a global cell therapy CDMO and testing partner. The company is headquartered in Philadelphia, Pennsylvania.
With modern facilities approved for commercial production in the United States (Allendale, NJ and Philadelphia), Europe (Munich) and Asia-Pacific (Yokohama, Japan), Minaris Advanced Therapies manufactures clinical-stage and commercial products on three continents and has a proven track record of delivering more than 7,500 GMP batches.
The company currently manufactures two commercial cell therapies and provides testing services for more than 27 commercial products. The company's capabilities include innovative platforms, development and manufacturing capabilities for cell therapies and viral vectors, and extensive testing services. With more than 25 years of cell therapy CDMO experience and over 40 years of experience in biosafety testing and product characterization, the new company will support the next wave of commercial cell therapies.
"CDMOs supporting the cell therapy industry have struggled to evolve from a small-scale cottage industry to deliver cost effective manufacturing at scale," said Iain Baird, chairman of Minaris Advanced Therapies. "Our mission is to solve the development and manufacturing challenges preventing these promising therapies from successful worldwide commercialization."
The team includes more than 1,400 industry professionals with deep scientific and regulatory expertise. The company's testing business unit provides unrivalled expertise in analytical method development and GMP-grade biosafety and product characterization testing services for both in-house and external programs.
"Minaris Advanced Therapies is designed to help the industry treat more patients by providing the experience, global footprint, and platforms to accelerate timelines and enable commercialization," said Eytan Abraham, Ph.D., chief commercial and technology officer. "Many of the technologies needed to reduce cost of goods sold and improve turnaround time already exist, we will drive their adoption and implementation at scale."
Built for speed, scale and science
Minaris Advanced Therapies brings together:
About Minaris Advanced Therapies
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 730,000 square feet of infrastructure across the United States, Europe and Asia. We have manufactured and released over 7,500 GMP batches and our global network supports therapy developers through early-stage development, clinical trials and commercial manufacturing. By combining scientific expertise with best-in-class manufacturing and testing services, we help bring safe, effective therapies to patients faster and more efficiently. Visit minaris.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 hours ago
- Korea Herald
Xinhua Silk Road: China Weihai, S. Korea Incheon building up momentum to bolster local cooperation
BEIJING, June 8, 2025 /PRNewswire/ -- As east China's Shandong Weihai and Incheon of South Korea embrace the 10th anniversary of building the local economic cooperation demonstration zone under the framework of China-South Korea Free Trade Agreement, the two sides have set new model for local cooperation between the two countries. Over the past decade, Weihai has forged new pathways for cooperation in areas such as mechanism building, trade, cultural exchanges and investment, with both sides engaging in comprehensive cooperation and achieving mutual benefits. For mechanism building, Weihai has established the China-South Korea Free Trade Area local economic cooperation coordination office and promotion center and issued documents to guide and promote the construction of the demonstration zone. Weihai and Incheon jointly set up the local economic cooperation joint committee, which has facilitated over a hundred of cooperation consensuses. For cultural exchanges, the two cities have established representative offices and promotion halls to boost understanding and interactions. The China Office of the Incheon Tourism Organization was established last October, creating a more efficient platform for Weihai and South Korea in tourism cooperation, products promotion, and resource sharing. In terms of economic and trade cooperation, Weihai has advanced innovative measures such as the Weihai-Incheon four ports logistics integration and the multimodal transport which have established a "golden channel" that spurred vigorous trade development. Trade between Weihai and South Korea increased 67.8 percent from 32.09 billion yuan in 2014 to 53.86 billion yuan in 2024, accounting for 26.4 percent of the city's total imports and exports. In 2024, the Weihai port's imports and exports with South Korea reached 154.07 billion yuan, ranking third in the country. Cross-border e-commerce has become a new driving force for Weihai's foreign trade development thanks to its unique geographical location and logistics advantages. The city's cross-border e-commerce retail exports to South Korea have ranked first in Shandong Province for seven consecutive years and ranked first in the country in 2024. In terms of investment, the number of South Korean-funded enterprises in Weihai increased by nearly 200 from 2014 to 2024, while the number of enterprises (or institutions) invested and established by Weihai in South Korea increased from 15 in 2014 to 62 in 2024 with contracted investment amount from the Chinese side doubling to reach 140 million U.S. dollars.
Korea Herald
5 hours ago
- Korea Herald
Xinhua Silk Road: South Korea Gangwon to deepen pragmatic economic and cultural cooperation with E China Anhui, official
BEIJING, June 8, 2025 /PRNewswire/ -- Gangwon of South Korea and east China's Anhui Province have a solid foundation for deeper cooperation after nearly a decade of friendship province relationship that was established in 2015, according to Gangwon Vice Governor Yeo Zhong Hyup, calling for more cooperation in economy, culture, arts, tourism, sports, education, and the environment between the two sides. The vice governor made the remarks during the opening ceremony of the 2025 RCEP Local Governments and Friendship Cities Cooperation (Huangshan) Forum held on June 5 in Anhui's Huangshan City. The event also witnessed the signing of the agreement on further strengthening friendship relationship between Anhui and Gangwon. The full implementation of the Regional Comprehensive Economic Partnership (RCEP) has provided new opportunities for local economies and cooperation at the local government level, in particular, played an indispensable role in promoting these opportunities towards practical development, the official noted. "RCEP is not only the world's largest free trade pact, but also a core platform for transforming regional cooperation potential into actual competitiveness," said the vice governor. For cultural and people-to-people exchanges, the official also introduced Gangwon's tourism resources in his speech such as its beautiful beaches, large ski resorts, and warm, comfortable guesthouses and welcome more Chinese tourists to visit Gangwon.
Korea Herald
a day ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
